David Veesler

This study identifies the endothelial protein C receptor (EPCR) as the entry receptor for Langya virus and reveals the molecular basis of its interaction with the viral attachment glycoprotein.

This study determines the structure of the 2026 Bundibugyo virus glycoprotein and identifies conserved epitopes for antibody therapeutics and pan-ebolavirus vaccines.

The paper shows how SARS-CoV-2 variants, particularly Omicron, evolved proteolytic controls at the Spike furin cleavage site to enhance transmission while reducing lower respiratory tract pathogenicity.

This paper computationally designs thermostable miniproteins that neutralize Nipah and Hendra viruses with subnanomolar affinity and potent in vitro antiviral activity.

This paper identifies a monoclonal antibody, PVA269, that broadly neutralizes multiple parainfluenza viruses by targeting the HN glycoprotein, showing potent prophylactic activity in a cotton rat model.

The paper shows repeated SARS-CoV-2 vaccine boosters elicit variant-specific memory B cells and neutralizing antibodies, suggesting immune imprinting can be overcome with updated vaccines.

The paper examines how mutations in the HCoV-229E spike affect receptor binding and serum neutralization, revealing counterbalancing effects on these functions.

This study measures the functional and antigenic effects of ~8,500 F protein mutations in Nipah virus using pseudoviruses, revealing constraints on its structure and neutralization by antibodies.

This paper develops a stabilized MERS-CoV spike ferritin nanoparticle vaccine that elicits strong neutralizing antibodies in mice and non-human primates, providing protection against MERS-CoV infection.

This paper describes a miniprotein inhibitor that neutralizes multiple SARS-CoV-2 variants and protects mice against them when administered post-exposure.

This paper develops an mRNA-launched nanoparticle vaccine that combines protein nanoparticle and mRNA vaccine advantages, showing enhanced antibody and T cell responses in mice.

This study designs miniproteins that inhibit MERS-CoV by targeting the spike protein, showing broad neutralization and protective efficacy in mice.

This study identifies a potent monoclonal antibody, MARV16, that broadly neutralizes Marburg virus and related viruses, with a cryo-EM structure revealing its mechanism of action.

This paper designs multivalent RBD nanoparticle vaccines that overcome immune imprinting and provide broad protection against SARS-CoV-2 variants and sarbecoviruses.

This study shows SARS-CoV-2 nsp1 inhibits translation in bat cells and human cells, revealing its broad activity across mammals.

The paper identifies teichuronic acid oligosaccharides as the receptor for umbrella toxins and shows targeting specificity arises from lectin domain recognition of variable TUA-WTA structures.

This study uses deep mutational scanning to analyze how mutations in the Nipah virus receptor-binding protein affect function, receptor binding, and antibody escape, revealing constrained regions and limited antigenic variation in natural strains.

The paper shows that HKU25 clade MERS-related coronaviruses use ACE2 as a receptor, challenging prior beliefs that DPP4 was their main receptor.

HKU5 merbecoviruses use bat Pipistrellus abramus ACE2 and several artiodactyl ACE2s through a cryo-EM-defined binding mode distinct from other ACE2-using coronaviruses, showing independent evolution of ACE2 usage.

This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.

The paper isolates two human monoclonal antibodies that broadly neutralize PDCoV variants and identifies their mechanism of action.

This paper develops a method to engineer customized viral receptors (CVRs) for various coronaviruses, enabling infection models for viruses lacking known receptors.

This study computationally stabilizes and characterizes herpesvirus gB trimers, revealing a new mechanism of fusion and providing a blueprint for vaccine development.

This study identifies molecular mechanisms of FCoV-23 pathogenicity, including receptor usage and biotype switching, and identifies a cross-reactive antibody for therapeutic development.

This study maps immunodominant sites on MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans, showing peak neutralizing activity against S1 and RBD epitopes.

This study determines the structure of HKU1 spike RBD bound to TMPRSS2, identifies host receptor usage determinants, and shows the role of antibodies and glycan shielding in neutralization.

This study uses deep mutational scanning to assess how mutations in SARS-CoV-2 spike proteins affect ACE2 binding, cell entry, and serum escape, linking these effects to clade growth rates.

This paper develops a stabilization strategy for sarbecovirus fusion machinery vaccines, showing broad reactivity and protection against SARS-CoV-2 variants.

This study identifies umbrella toxin particles produced by Streptomyces that inhibit the growth of competing bacterial species, distinct from small molecule antibiotics.

This study shows that immune imprinting from prior Wuhan-Hu-1 spike exposure persists after XBB.1.5 vaccine booster, with neutralizing antibodies dominated by pre-existing memory B cells.